Radius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine and other therapeutics. The company markets TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trial for the treatment of osteoporosis in men; abaloparatide transdermal patch, a short-wear-time transdermal patch, that is in Phase III clinical trial to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trial for the treatment of hormone receptor-positive breast cancer; and RAD011, which is in Phase II clinical trial for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts.
Read More